⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.06
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,690.05
−0.01%
Nasdaq 100
29,321.22
−0.70%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,151.64
−0.49%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$215.25
−0.85%
NYSE:TSM
$420.67
+0.11%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,122.74
−0.44%
Brent
$109.11
−0.10%
BTC
$82,330.76
+0.60%
ETH
$2,418.79
+0.57%
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.06
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,690.05
−0.01%
Nasdaq 100
29,321.22
−0.70%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,151.64
−0.49%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$215.25
−0.85%
NYSE:TSM
$420.67
+0.11%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,122.74
−0.44%
Brent
$109.11
−0.10%
BTC
$82,330.76
+0.60%
ETH
$2,418.79
+0.57%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Closed
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Open
🇮🇳
India
NSE · BSE · Nifty 50
Closed
🇵🇰
Pakistan
PSX · KSE-100
Closed
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Bristol-Myers Squibb Co · News · TradingHolo
Markets
›
United States
› NYSE
› BMY
B
Bristol-Myers Squibb Co
NYSE:BMY
Healthcare
CBOE:SPESG
STOXX:EDD24BP
$58.83
−1.54%
At close
At close · Tue 20 Oct · ≈
AED 216.05
· Market cap
$120.17B
· Next earnings
Thu 29 Oct
· Extended
$59.30
+0.80%
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
BMY news
Headlines tagged to this company
SE
Looming biosimilar void risks $189B in lost U.S. healthcare savings: report
seekingalpha · 33 d ago
BE
Bristol Myers Squibb’s Psoriatic Arthritis Pill Shows Durable Efficacy After Two Years
benzinga · 33 d ago
SE
Roche succeeds in late-stage study for Lunsumio regimen in follicular lymphoma
seekingalpha · 33 d ago
SE
Undervalued healthcare stocks with attractive valuation grades
seekingalpha · 35 d ago
SE
FDA launches pilot program that aims to speed the time to first-in-human drug trials
seekingalpha · 35 d ago
SE
AM Markets Need to Know: Diesel tops $6, DeepSeek pressures chips, and more
seekingalpha · 39 d ago
SE
Trump's surgeon general pick discloses tobacco, fast food and soda investments
seekingalpha · 39 d ago
ZA
BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?
zacks · 40 d ago
SE
25 dividend stocks to watch as market sentiment turns negative
seekingalpha · 41 d ago
ZA
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?
zacks · 41 d ago
SE
Ten healthcare stocks with A-rated valuations and strong revenue growth
seekingalpha · 41 d ago
BE
Bristol Myers Says Cell Therapy Shows Promise For Heavily Pretreated Blood Cancer Patients
benzinga · 42 d ago
BA
Bristol Myers Swoons on Test Results
baystreet · 42 d ago
ZA
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Zacks Investment Research · 62 d ago
ZA
Can BMY's First CELMoD Approval Support Its Growth Strategy?
Zacks Investment Research · 67 d ago
BU
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Business Wire · 68 d ago
RE
US FDA approves Bristol Myers' blood cancer treatment
Reuters · 68 d ago
RE
Lawsuit against Bristol Myers over delayed cancer drug is revived
Reuters · 68 d ago
ZA
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?
Zacks Investment Research · 69 d ago
ZA
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?
Zacks Investment Research · 71 d ago
← Previous
More news →